Back to 2014 Annual Meeting Posters

OBJECTIVE: Perceval S Sutureless valve has shown excellent outcomes after isolated aortic valve replacement (AVR). However, no experience is reported on Perceval S in multiple valve surgery. The aim of our study is to report our single center experience in high-risk patients undergoing AVR combined with mitral and/or tricuspid valve surgery.
METHODS: This is a retrospective, observational study of prospectively collected data on 35 consecutive high-risk patients undergoing AVR with Perceval S valve and other valve procedures. Of these, 8 had previous cardiac surgery.
RESULTS: Twenty-seven patients underwent AVR+ mitral valve surgery (15 replacements and12 repairs), of which 2 had also tricuspid valve repair. Of the 8 redo patients, 5 had AVR after previous mitral valve surgery (3 replacement and 2 repairs) and 3 had AVR re-replacement associated with tricuspid surgery (1 replacement and 2 repairs). The mean cross clamp and cardiopulmonary bypass times were 93±32 min and 140±45 min, respectively. In hospital mortality was 2.8% (1/35) with an expected median logistic EuroSCORE I of 16% (range 4-74 %). Postoperative stroke and need of pacemaker implantation occurred in 2 patients,respectively. At median follow-up of 6 months, survival was 83%, freedom from reoperation was 100%. No paravalvular leakage occurred and the mean gradient at follow-up was 11±4 mmHg.
CONCLUSIONS: Aortic valve replacement with Perceval S sutureless valve in combined multiple valve surgery is a feasible and safe procedure associated with good early and 6-month outcomes.